HCI
ASBP

Harraden Circle Investments’s Aspire Biopharma ASBP Stock Holding History

Harraden Circle Investments’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-125
Closed -$87.4K – 142
2025
Q1 		$87.4K Sell
125
-250
-67% -$1.73M 0.04% 95
2024
Q4 		$5.17M Buy
+375
New +$5.3M 4.12% 8

Other funds holding ASBP

PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
CA
Crewe Advisors Salt Lake City, Utah $1.17B AUM 29.21% 1-Year Est. Return
OAS
Optivise Advisory Services Franklin, Tennessee $197M AUM 26.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VAS
VR Advisory Services Camana Bay, Grand Cayman, Cayman Islands $845M AUM 22.79% 1-Year Est. Return
TSW
Three Seasons Wealth Salt Lake City, Utah $262M AUM 45.03% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.55B AUM 28.47% 1-Year Est. Return
PTP
Platform Technology Partners New York $519M AUM 20% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Harraden Circle Investments's ASBP Position: Q2 2025 in Review

Harraden Circle Investments sold out of Aspire Biopharma (ASBP) in Q2 2025, closing a stake of 125 shares — an estimated $87.4K sold.

Harraden Circle Investments first reported a position in ASBP in Q4 2024 and held it in 2 quarters. The position peaked at $5.17M in Q4 2024. 14 funds tracked by Wall St. Rank hold ASBP as of Q2 2025.

  • Harraden Circle Investments reported no remaining Aspire Biopharma position as of Q2 2025 after selling out during the quarter.
  • Harraden Circle Investments sold 125 Aspire Biopharma shares in Q2 2025, an estimated $87.4K.
  • Harraden Circle Investments first reported a position in Aspire Biopharma in Q4 2024 and held it in 2 quarters.
  • Harraden Circle Investments's Aspire Biopharma position peaked at $5.17M in Q4 2024.
  • 14 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2025.

Based on Harraden Circle Investments's 13F filing for Q2 2025, filed 14 Aug 2025.